Clinical TrialJul 1, 2026, 07:31 AM
NorthStrive Biosciences Reports Positive Phase III Drug Results
AI Summary
NorthStrive Biosciences, a subsidiary of PMGC Holdings Inc., announced positive Phase III results from its AI-driven drug discovery program with strategic partner Yuva Biosciences. Yuva's MitoNova™ AI platform identified four small-molecule candidates (C1, C2, C3, C4) that significantly increased ANT1 protein expression in primary human skeletal muscle cells, a mitochondrial protein central to energy metabolism. The strongest candidates showed dose-dependent induction, with increases up to +50%. These results support advancing the candidates for further confirmatory testing and development in more mature muscle models.
Key Highlights
- Four AI-selected compounds (C1, C2, C3, C4) significantly increased ANT1 expression.
- C2 demonstrated up to a +50% increase in ANT1 expression.
- C4 demonstrated up to a +48% increase in ANT1 expression.
- C1 demonstrated up to a +46% increase in ANT1 expression.
- C3 showed a +29% increase at the highest tested dose.
- Yuva Biosciences recommended advancing all four validated candidates.
- Next steps include confirmatory testing in a more mature skeletal muscle model.
Price Impact
More from ELAB